Revlimid Articles

Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma

12 February 2013

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

3 October 2012

Celgene slumps as it pulls new EU indication filing for Revlimid

22 June 2012

Study shows benefit of new maintenance therapy for multiple myeloma

14 May 2012

US FDA warns on safety of Celgene's Revlimid; new Ph III trial results

11 May 2012

5.6% annual growth forecast for multiple myeloma drug market to 2020

21 December 2011

Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure

23 November 2011

Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report

1 November 2011

More news from EMA/CHMP September meeting

26 September 2011

Celgene presents positive new data on cancer drug Revlimid in combination with Rituxan

19 June 2011

Celgene makes regulatory submissions for Revlimid and Istodax

6 January 2011

Watson confirms deal with Natco for generic version of Celgene’s cancer drug Revlimid

8 December 2010

Celgene plunges on concerns of secondary malignancies with blockbuster multiple myeloma drug Revlimid; news from Novo Nordisk, B-MS at ASH

7 December 2010

India’s Natco challenges Celgene’s Revlimid patent in USA; new CFO named

6 September 2010

26 August 2010

In Japan, Celgene’s Revlimid gets approval; Astellas to file degarelix and inks vaccine deal with UMN

23 August 2010

Datamonitor views big brand survival in shrinking anti-hormanal cancer market; outlook for Celgene’s Revlimed

8 August 2010

Sustained MM responses with Celgene's Revlimid

8 June 2009

Merck & Co's vorinostat shows early efficacy in MM

8 June 2009

Stock Commentary - New York week to May 11, 2009

14 May 2009

UK's NICE guidance on VTE, multiple myeloma, glaucoma and ocular hypertension

6 May 2009

Biotech down on weaker 1st-qtr drug sales, but broader market stays on a roll

6 May 2009

Celgene swings back to profit in 1st qtr

5 May 2009

Celgene falls up to 17% on low 1st-qtr forecast

3 April 2009

NICE in cost-sharing deal for MM drug

9 February 2009

Sutent available in England, not Scotland

9 February 2009

Celgene reports initial 2008 figures

26 January 2009

Zolinza/Velcade combo enters Ph IIb MM trial

26 January 2009

EntreMed initiates Ph I MM study

15 December 2008

Millennium presents Ph I Velcade trial results

15 December 2008

High activity for Vidaza/Revlimid combo in Ph I MDS study

15 December 2008

Celgene's 3rd-qtr profit triples on drug sales

17 November 2008

UK cancer groups turn against Celgene over NICE refusal

10 November 2008

Celgene

13 October 2008

Celgene's Revlimid linked to 14 cases of serious skin reactions, says FDA report

29 September 2008

US presidential election heats up, health care lags behind economy and Iraq

22 September 2008

Scotland told not to allow Rx top ups

15 September 2008

US FDA posts first quarterly report of potential safety issues, cites eight drugs

15 September 2008

Revlimid effective in advanced NHL patients

8 September 2008

UK's NICE under fire from physicians over rationing, ABPI offers debate

1 September 2008

Celgene profits double on rocketing sales

11 August 2008

Promising Revlimid data in NHL

23 June 2008

No new indication for Celgene

16 June 2008

Celgene withdraws EU Revlimid MAA

9 June 2008

Celgene posts 1st-qtr loss on Pharmion costs

19 May 2008

EC clears Celgene's Thalidomide in MM

28 April 2008

Japan's MHLW grants Revlimid orphan status for two different indications

25 February 2008

UK's NICE asked to develop new clinical health guidance for DoH

18 February 2008

CHMP issues positive approval opinions

4 February 2008

Biotech has positive year, despite weak 2007 fourth quarter, says Burrill

21 January 2008

Celgene's

14 January 2008

EU orphan status for Celgene's Revlimid

10 December 2007

Celgene bids $2.9B for Pharmion; deal includes predicted blockbuster Vidaza

26 November 2007

Analysis indicates further Revlimid benefits in MM

26 November 2007

Millennium's 3rd-qtr loss down 88%

21 November 2007

Celgene's Revlimid gets nod from ADEC

19 November 2007

US MDS Foundation welcomes Vidaza data

10 September 2007

Celgene

10 September 2007

Recruitment opens in Ph II Velcade combo MM trial

20 August 2007

Celegene's 2nd-qtr 2007 income soars 187.2%

6 August 2007

Velcade produces 54% CR rate in MM

9 July 2007

Strong Ph I/II data for Keryx' perifosine

9 July 2007

Revlimid regimen improves survival in MM

9 July 2007

EC clears Celgene's Revlimid for MM

25 June 2007

Revlimid combo could become MM standard of care

18 June 2007

Nw drugs, obesity epidemic will drive US drug spending higher, says Medco

4 June 2007

Celgene's 1st-qtr 2007 net income soars 61.4%

28 May 2007

Revlimid plus low-dose dexamethasone for MM

16 April 2007

Three new drugs get nod from EMEA's CHMP

2 April 2007

MMRC and Keryx initiate Ph I KRX-0401 study

8 January 2007

US FDA clears Celgene's Revlimid for MM

10 July 2006

US FDA approves Revlimid for MM

10 July 2006

Celgene reports data from trials of Revlimid in MM, NHL and MDS at 11th annual EHA

26 June 2006

Early development of six pharma agents urged in Japan

8 May 2006

Celgene's Revlimid MMA accepted by EMEA

17 April 2006

US mid-cap biotech stocks post solid gains in February, says Burrill report

20 March 2006

Celgene's Revlimid gets FDA priority review

13 March 2006

Celgene's profits nosedive 82%

6 February 2006

Celgene expects 30% rise in 2005 income

16 January 2006

Celgene received FDA approval for Revlimid in MDS anemia

9 January 2006

Celgene's Revlimid betters MM outcomes

19 December 2005

Celgene's Revlimid patients show good response to MDS

13 June 2005

Revlimid found to prolong time to progression of multiple myeloma

30 May 2005

Recent oncology R&D advances and Big Pharma's competitive struggle: study

28 April 2005

Celgene posts initial data from Phase III Revlimid study

25 April 2005

Celgene submits Revlimid NDA to FDA

18 April 2005

Celgene's Revlimid Ph III trials meet endpoint

14 March 2005

Study sees biotech losing ground in May, as US economy stalls, IPO market softens

14 June 2004

Celgene halts Revlimid trial

10 May 2004

Biotechnology firms "raised more money than ever" in first-quarter 2004

19 April 2004

Revlimid gets Orphan Drug status for MDS in EU

15 March 2004

Revlimid gets Orphan Drug status in EU

1 March 2004